This video reviews immunotherapy options now available for the treatment of lung cancer across different lines of therapy.
In this video, Melissa L. Johnson, MD, of Sarah Cannon Research Institute in Nashville, Tennessee, reviews immunotherapy options now available for the treatment of lung cancer across different lines of therapy and highlights upcoming research in this setting.
Johnson gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting last month in Chicago.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.